Business Overview Relmada Therapeutics, Inc. (Relmada, the Company, we or us) (a Nevada corporation), is a publicly traded, clinical-stage biotechnology company. We substantially redesigned our development programs following a comprehensive strategic review in late 2024 and early 2025. We concluded in our review that the most promising path to create shareholder value was to lever our extensive drug development expertise and clinical operations capabilities by acquiring new development candidate...
Q2 FY2026 — expected 2026-09-11
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-19 | 2025-12-31 | 0001213900-26-031862 | EDGAR | 49K words |
| 2025-03-27 | 2024-12-31 | 0001013762-25-003426 | EDGAR | — |
| 2024-03-19 | 2023-12-31 | 0001213900-24-024013 | EDGAR | — |
| 2023-03-23 | 2022-12-31 | 0001213900-23-022463 | EDGAR | — |
| 2022-03-25 | 2021-12-31 | 0001213900-22-015012 | EDGAR | — |
| 2021-03-24 | 2020-12-31 | 0001213900-21-017556 | EDGAR | — |
| 2019-09-24 | 2019-06-30 | 0001213900-19-018787 | EDGAR | — |
| 2018-09-28 | 2018-06-30 | 0001213900-18-013238 | EDGAR | — |
| 2017-09-28 | 2017-06-30 | 0001213900-17-010097 | EDGAR | — |
| 2016-09-09 | 2016-06-30 | 0001213900-16-016664 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-06 | 2026-06-30 | 0001213900-26-086151 | EDGAR | — |
| 2025-11-13 | 2025-09-30 | 0001213900-25-109983 | EDGAR | 17K words |
| 2025-08-07 | 2025-06-30 | 0001213900-25-073073 | EDGAR | — |
| 2025-05-12 | 2025-03-31 | 0001213900-25-042025 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0001213900-24-095398 | EDGAR | — |
| 2024-08-07 | 2024-06-30 | 0001213900-24-066111 | EDGAR | — |
| 2024-05-08 | 2024-03-31 | 0001213900-24-040856 | EDGAR | — |
| 2023-11-08 | 2023-09-30 | 0001213900-23-084737 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0001213900-23-064519 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0001213900-23-038533 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0001213900-22-071154 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0001213900-22-046934 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-06 | 0001213900-26-086190 | EDGAR | — |
| 2026-07-28 | 0001213900-26-082007 | EDGAR | — |
| 2026-03-20 | 0001213900-26-032403 | EDGAR | 4K words |
| 2026-03-09 | 0001213900-26-024918 | EDGAR | — |
| 2025-12-15 | 0001213900-25-121461 | EDGAR | — |
| 2025-11-13 | 0001213900-25-110088 | EDGAR | — |
| 2025-11-05 | 0001213900-25-106398 | EDGAR | — |
| 2025-11-04 | 0001213900-25-105593 | EDGAR | — |
| 2025-09-17 | 0001213900-25-088360 | EDGAR | — |
| 2025-09-16 | 0001213900-25-087926 | EDGAR | — |
239 total filings indexed. 207 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001553643 |
| Ticker | RLMD |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | NV |
| Website | https://www.relmada.com |
| Listed | 2014-03-03 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/RLMD (~200 tokens, structured JSON with cryptographic provenance)